Searched for
RLL
Buy Raymond Lifestyle, target price Rs 3,000: Motilal Oswal Financial ServicesMotilal Oswal Financial Services recommends buying Raymond Lifestyle, targeting a price of Rs 3,000. Currently priced at Rs 2052.05, Raymon...- Raymond Lifestyle shares rally 3% as Motilal Oswal predicts 29% upsideRaymond Lifestyle's shares rose 3.4% after Motilal Oswal projected a 29% upside, with a target of Rs 3,000. The growth outlook is fueled by...
- Motilal Oswal predicts 35% upside in Raymond Lifestyles, initiates coverage with ‘buy’ ratingMotilal Oswal has begun coverage of Raymond Lifestyle (RLL) with a buy rating and a target price of Rs 3,200, anticipating a transformative...
- Raymond shares surge 8% in 2 days ahead of lifestyle business’ listing tomorrowRaymond Share Price: Raymond's shares rose by 8% over two days, reaching Rs 2,179 on the BSE. This surge comes ahead of the listing of its ...
- Raymond shares jump 9% ahead of listing of lifestyle business. Here's whyRaymond Share Price: Raymond shares jumped 9% to Rs 2,182 ahead of its lifestyle business listing this week. Brokerages, including Motilal ...
- Raymond shares trade ex-lifestyle business, stock jumps over 4%Raymond's lifestyle business demerger process begins with shareholders receiving new equity shares. The company's stock price rises by near...
- India-Russia trade body endorses new framework to 15 projectsThe projects include setting-up of JV with HAL as joint centre for development of helicopters, joint project of RLL and government of Yaros...
- Ranbaxy launches anti-acne drug in the US marketAccording to an analyst, the launch of Absorica would greatly benefit Ranbaxy as there are only 2-3 players currently selling the product i...
- Ranbaxy labs gets Health Canada nod for cholesterol lowering drugRanbaxy Labs said it has received approval from the Health Canada to manufacture & mkt its generic RAN-Rosuvastatin tablets used for loweri...
- HDFC recommends 'sell' on Ranbaxy for target of Rs 230HDFC Securities has downgraded Ranbaxy Laboratories (RLL) from Hold to “Sell” with a price target of Rs 230 per share in its post-result up...
- Lupin buys Baroda co RubaminRLL, a subsidiary of the Rubamin group, manufactures advanced intermediates and Active Pharmaceutical Ingredients (APIs) and provides resea...
- Lupin acquires pharma business of RubaminDrug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.
- Ranbaxy receives USFDA's nod for pain reliefRanbaxy Laboratories to manufacture and market Hydrocodone Bitartrate and Acetaminophen tablets in the US.
- Gets Norway nod to market Atorvastatin eRanbaxy Laboratories (RLL) announced that the Norwegian Appeals Court has given a favourable decision for Ranbaxy in its case against Pfize...
- Ranbaxy wins on all 4 Atorvastatin Patents in NorwayRanbaxy Laboratories Limited (RLL) announced that the Norwegian Appeals Court today handed down a favorable decision for Ranbaxy in its cas...
- Ranbaxy gets US nod to mkt its drugGurgaon-based pharmaceutical major Ranbaxy Labs today announced that RLL has received approval from the US Food and Drug Administration to ...
- Ranbaxy to mkt hypertension drug in USThe company has got FDA approval to market atenolol tablets of strengths 25 mg, 50 mg, and 100 mg.
- Ranbaxy wins on two additional patents in NorwayIn yet another boost to India's biggest drug maker Ranbaxy Laboratories, a Norwegian court has ruled in its favour in the patent litigation...
- Ranbaxy gets approval to produce, sell anti-AIDS drugCountry's largest drug maker, Ranbaxy Laboratories Limited (RLL) on Monday said it had received approval to manufacture and market anti-AID...
- Ranbaxy gets USFDA nod for antibioticRanbaxy Laboratories Limited (RLL) on Friday said it had received approval from the US Food and Drug Administration to manufacture and mark...
Load More
